Treatment of childhood germ cell tumors: Review of the St. Jude experience from 1979 to 1988

Neyssa Marina, James Fontanesi, Larry Kun, Bhaskar Rao, Jesse J. Jenkins, Elizabeth I. Thompson, Erlinda Etcubanas

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background. The outlook for patients with germ cell tumors was poor before the advent of effective chemotherapy. The authors assessed the outcome of treatment with multiagent chemotherapy (with or without radiation therapy) in children treated for germ cell tumors at St. Jude Children's Research Hospital (SJCRH). Methods. Sixty children with germ cell tumors were treated between January 1979 and June 1988. Post‐surgical treatment was based on tumor site, stage, and histology. Most patients received chemotherapy with vincristine, actinomycin‐D, and cyclophosphamide (VAC), or a modified Einhorn regimen (cisplatin, bleomycin, and vinblastine [PVB]); in the absence of response to initial therapy, patients received alternating courses of VAC and PVB (VAC/PVB regimen). Exceptions were patients with Stage I testicular tumors (observation only) and ovarian germinomas (Stage I tumors measuring less than 10 cm, observation only; tumors larger than 10 cm or Stage II‐III disease, radiation only; and Stage IV disease, VAC plus radiation). Results. The estimated 5‐year survival is 100% for patients with Stage I disease (n = 18), 87% for patients with Stage II (n = 8), 72% for Stage III (n = 25), and 56% for Stage IV (n = 9). Patients with testicular tumors of any stage or with Stage I‐II ovarian tumors had 100% 5‐year survival. Extragonadal tumors responded poorly to VAC alone with recurrent or progressive disease in eight of nine patients. Treatment for those tumors was changed to alternating courses of VAC and PVB, which failed in only one of seven patients. Nine of 19 patients with advanced ovarian tumors had disease recurrence with VAC; these patients then received PVB, which was effective in four cases. Conclusions. For patients with advanced germ cell cancers, intensification of therapy or the development of new approaches is necessary. In contrast, future trials in children with limited stage should focus on reducing acute and long‐term toxicities.

Original languageEnglish (US)
Pages (from-to)2568-2575
Number of pages8
JournalCancer
Volume70
Issue number10
DOIs
StatePublished - Jan 1 1992

Fingerprint

Germ Cell and Embryonal Neoplasms
Vincristine
Cyclophosphamide
Therapeutics
Neoplasms
Testicular Neoplasms
Drug Therapy
Observation
Germinoma
Radiation
Survival
Vinblastine
Bleomycin
Cisplatin
Histology
Radiotherapy

Keywords

  • chemotherapy
  • childhood cancer
  • germ cell tumors
  • solid tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Marina, N., Fontanesi, J., Kun, L., Rao, B., Jenkins, J. J., Thompson, E. I., & Etcubanas, E. (1992). Treatment of childhood germ cell tumors: Review of the St. Jude experience from 1979 to 1988. Cancer, 70(10), 2568-2575. https://doi.org/10.1002/1097-0142(19921115)70:10<2568::AID-CNCR2820701028>3.0.CO;2-1

Treatment of childhood germ cell tumors : Review of the St. Jude experience from 1979 to 1988. / Marina, Neyssa; Fontanesi, James; Kun, Larry; Rao, Bhaskar; Jenkins, Jesse J.; Thompson, Elizabeth I.; Etcubanas, Erlinda.

In: Cancer, Vol. 70, No. 10, 01.01.1992, p. 2568-2575.

Research output: Contribution to journalArticle

Marina, N, Fontanesi, J, Kun, L, Rao, B, Jenkins, JJ, Thompson, EI & Etcubanas, E 1992, 'Treatment of childhood germ cell tumors: Review of the St. Jude experience from 1979 to 1988', Cancer, vol. 70, no. 10, pp. 2568-2575. https://doi.org/10.1002/1097-0142(19921115)70:10<2568::AID-CNCR2820701028>3.0.CO;2-1
Marina, Neyssa ; Fontanesi, James ; Kun, Larry ; Rao, Bhaskar ; Jenkins, Jesse J. ; Thompson, Elizabeth I. ; Etcubanas, Erlinda. / Treatment of childhood germ cell tumors : Review of the St. Jude experience from 1979 to 1988. In: Cancer. 1992 ; Vol. 70, No. 10. pp. 2568-2575.
@article{89e0dd1e04554333950c73943569180c,
title = "Treatment of childhood germ cell tumors: Review of the St. Jude experience from 1979 to 1988",
abstract = "Background. The outlook for patients with germ cell tumors was poor before the advent of effective chemotherapy. The authors assessed the outcome of treatment with multiagent chemotherapy (with or without radiation therapy) in children treated for germ cell tumors at St. Jude Children's Research Hospital (SJCRH). Methods. Sixty children with germ cell tumors were treated between January 1979 and June 1988. Post‐surgical treatment was based on tumor site, stage, and histology. Most patients received chemotherapy with vincristine, actinomycin‐D, and cyclophosphamide (VAC), or a modified Einhorn regimen (cisplatin, bleomycin, and vinblastine [PVB]); in the absence of response to initial therapy, patients received alternating courses of VAC and PVB (VAC/PVB regimen). Exceptions were patients with Stage I testicular tumors (observation only) and ovarian germinomas (Stage I tumors measuring less than 10 cm, observation only; tumors larger than 10 cm or Stage II‐III disease, radiation only; and Stage IV disease, VAC plus radiation). Results. The estimated 5‐year survival is 100{\%} for patients with Stage I disease (n = 18), 87{\%} for patients with Stage II (n = 8), 72{\%} for Stage III (n = 25), and 56{\%} for Stage IV (n = 9). Patients with testicular tumors of any stage or with Stage I‐II ovarian tumors had 100{\%} 5‐year survival. Extragonadal tumors responded poorly to VAC alone with recurrent or progressive disease in eight of nine patients. Treatment for those tumors was changed to alternating courses of VAC and PVB, which failed in only one of seven patients. Nine of 19 patients with advanced ovarian tumors had disease recurrence with VAC; these patients then received PVB, which was effective in four cases. Conclusions. For patients with advanced germ cell cancers, intensification of therapy or the development of new approaches is necessary. In contrast, future trials in children with limited stage should focus on reducing acute and long‐term toxicities.",
keywords = "chemotherapy, childhood cancer, germ cell tumors, solid tumors",
author = "Neyssa Marina and James Fontanesi and Larry Kun and Bhaskar Rao and Jenkins, {Jesse J.} and Thompson, {Elizabeth I.} and Erlinda Etcubanas",
year = "1992",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19921115)70:10<2568::AID-CNCR2820701028>3.0.CO;2-1",
language = "English (US)",
volume = "70",
pages = "2568--2575",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Treatment of childhood germ cell tumors

T2 - Review of the St. Jude experience from 1979 to 1988

AU - Marina, Neyssa

AU - Fontanesi, James

AU - Kun, Larry

AU - Rao, Bhaskar

AU - Jenkins, Jesse J.

AU - Thompson, Elizabeth I.

AU - Etcubanas, Erlinda

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Background. The outlook for patients with germ cell tumors was poor before the advent of effective chemotherapy. The authors assessed the outcome of treatment with multiagent chemotherapy (with or without radiation therapy) in children treated for germ cell tumors at St. Jude Children's Research Hospital (SJCRH). Methods. Sixty children with germ cell tumors were treated between January 1979 and June 1988. Post‐surgical treatment was based on tumor site, stage, and histology. Most patients received chemotherapy with vincristine, actinomycin‐D, and cyclophosphamide (VAC), or a modified Einhorn regimen (cisplatin, bleomycin, and vinblastine [PVB]); in the absence of response to initial therapy, patients received alternating courses of VAC and PVB (VAC/PVB regimen). Exceptions were patients with Stage I testicular tumors (observation only) and ovarian germinomas (Stage I tumors measuring less than 10 cm, observation only; tumors larger than 10 cm or Stage II‐III disease, radiation only; and Stage IV disease, VAC plus radiation). Results. The estimated 5‐year survival is 100% for patients with Stage I disease (n = 18), 87% for patients with Stage II (n = 8), 72% for Stage III (n = 25), and 56% for Stage IV (n = 9). Patients with testicular tumors of any stage or with Stage I‐II ovarian tumors had 100% 5‐year survival. Extragonadal tumors responded poorly to VAC alone with recurrent or progressive disease in eight of nine patients. Treatment for those tumors was changed to alternating courses of VAC and PVB, which failed in only one of seven patients. Nine of 19 patients with advanced ovarian tumors had disease recurrence with VAC; these patients then received PVB, which was effective in four cases. Conclusions. For patients with advanced germ cell cancers, intensification of therapy or the development of new approaches is necessary. In contrast, future trials in children with limited stage should focus on reducing acute and long‐term toxicities.

AB - Background. The outlook for patients with germ cell tumors was poor before the advent of effective chemotherapy. The authors assessed the outcome of treatment with multiagent chemotherapy (with or without radiation therapy) in children treated for germ cell tumors at St. Jude Children's Research Hospital (SJCRH). Methods. Sixty children with germ cell tumors were treated between January 1979 and June 1988. Post‐surgical treatment was based on tumor site, stage, and histology. Most patients received chemotherapy with vincristine, actinomycin‐D, and cyclophosphamide (VAC), or a modified Einhorn regimen (cisplatin, bleomycin, and vinblastine [PVB]); in the absence of response to initial therapy, patients received alternating courses of VAC and PVB (VAC/PVB regimen). Exceptions were patients with Stage I testicular tumors (observation only) and ovarian germinomas (Stage I tumors measuring less than 10 cm, observation only; tumors larger than 10 cm or Stage II‐III disease, radiation only; and Stage IV disease, VAC plus radiation). Results. The estimated 5‐year survival is 100% for patients with Stage I disease (n = 18), 87% for patients with Stage II (n = 8), 72% for Stage III (n = 25), and 56% for Stage IV (n = 9). Patients with testicular tumors of any stage or with Stage I‐II ovarian tumors had 100% 5‐year survival. Extragonadal tumors responded poorly to VAC alone with recurrent or progressive disease in eight of nine patients. Treatment for those tumors was changed to alternating courses of VAC and PVB, which failed in only one of seven patients. Nine of 19 patients with advanced ovarian tumors had disease recurrence with VAC; these patients then received PVB, which was effective in four cases. Conclusions. For patients with advanced germ cell cancers, intensification of therapy or the development of new approaches is necessary. In contrast, future trials in children with limited stage should focus on reducing acute and long‐term toxicities.

KW - chemotherapy

KW - childhood cancer

KW - germ cell tumors

KW - solid tumors

UR - http://www.scopus.com/inward/record.url?scp=0026495874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026495874&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19921115)70:10<2568::AID-CNCR2820701028>3.0.CO;2-1

DO - 10.1002/1097-0142(19921115)70:10<2568::AID-CNCR2820701028>3.0.CO;2-1

M3 - Article

C2 - 1384951

AN - SCOPUS:0026495874

VL - 70

SP - 2568

EP - 2575

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -